KPTI on Nasdaq

Karyopharm Therapeutics Inc.

American pharmaceutical preparations company based in Newton, active since 2008.

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with Clovis Oncology, ELITE PHARMACEUTICALS INC /NV/ or MACROGENICS INC, or pick any stock.

  • TickerKPTI on Nasdaq
  • IndustryPharmaceutical Preparations
  • HeadquartersWilmington, United States
  • Incorporated inDE2
  • Business address85 Wells Avenue, Second Floor, Newton, Ma 024592
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-62.1%Operating margin3
-134.2%Net margin3
0.6%Revenue growth, 20253
-$75.4MFree cash flow3

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Product brought in 79% of the revenue Karyopharm Therapeutics Inc. broke down this way in fiscal 2025.

  1. Product$114.9M379%up 2% from 2024
  2. License And Other$31.2M321%down 4% from 2024
Products and services by year
Products and services202320242025
Product$112.0M$112.8M$114.9M
License And Other$34.0M$32.4M$31.2M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development54¢$125.6M
  • Selling, general and admin46¢$105.2M
  • Income tax0¢$43.0K

Out of $146.1M in revenue.3 The company lost money this year.

Financial statements

Revenue45673$146.1M in 2025+257% since 2019
0$100.0M$200.0M$300.0M2019: $40.9M$40.9M20192020: $108.1M$108.1M2020+164%2021: $209.8M$209.8M2021+94%2022: $157.1M$157.1M2022−25%2023: $146.0M$146.0M2023−7%2024: $145.2M$145.2M2024−1%2025: $146.1M$146.1M2025+1%
Operating income45673-$90.7M in 2025−52% since 2019
-$200.0M-$150.0M-$100.0M-$50.0M02019: -$189.3M-$189.3M20192020: -$171.8M-$171.8M2020−9%2021: -$98.3M-$98.3M2021−43%2022: -$142.2M-$142.2M2022+45%2023: -$129.5M-$129.5M2023−9%2024: -$119.4M-$119.4M2024−8%2025: -$90.7M-$90.7M2025−24%
Net income45673-$196.0M in 2025−2% since 2019
-$200.0M-$150.0M-$100.0M-$50.0M02019: -$199.6M-$199.6M20192020: -$196.3M-$196.3M2020−2%2021: -$124.1M-$124.1M2021−37%2022: -$165.3M-$165.3M2022+33%2023: -$143.1M-$143.1M2023−13%2024: -$76.4M-$76.4M2024−47%2025: -$196.0M-$196.0M2025+157%

Every line of the income statement as filed: the last 3 fiscal years, latest first.3

Period ending2025-12-312024-12-312023-12-31
Revenue from contract with customer, license and other revenue$146.1M$145.2M$146.0M
Research and development$125.6M$143.2M$138.8M
Selling, general and administrative$105.2M$115.4M$131.9M
Total operating expenses$236.8M$264.7M$275.6M
Loss from operations-$90.7M-$119.4M-$129.5M
Interest income$2.8M$7.4M$10.9M
Interest expense-$45.8M-$37.4M-$23.8M
(Loss) gain on extinguishment of debt-$62.4M$44.7M$0
Other income (expense), net$152.0K$28.4M-$356.0K
Total other (expense) income, net-$105.3M$43.1M-$13.2M
Loss before income taxes-$196.0M-$76.4M-$142.8M
Income tax provision-$43.0K-$57.0K-$323.0K
Net loss-$196.0M-$76.4M-$143.1M
Basic net loss per share-$17.93-$9.41-$18.79
Diluted net loss per share (Note 2)-$17.93-$14.00-$18.79
Weighted-average number of common shares outstanding used to compute basic net loss per share10.9K shares8.1K shares7.6K shares
Weighted-average number of common shares outstanding used to compute diluted net loss per share10.9K shares8.5K shares7.6K shares

Compare Karyopharm Therapeutics Inc. with another company

Leadership

Who has led Karyopharm Therapeutics Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Michael Kauffman2013–2021
  2. Richard A. Paulson2021–now

President

  1. Michael Kauffman2013
  2. Sharon Shacham2014–2021
  3. Richard A. Paulson2021–now

Chief financial officer

  1. Justin A. Renz2014–2017
  2. Michael Falvey2017–2018
  3. Lori Macomber2025–now
201520202025
Board members and other officers (29)

Timeline

  1. May 4, 2021New chief executive Richard A. Paulson becomes CEO11
  2. Nov 13, 2013New chief executive Michael Kauffman becomes CEO12
  3. Dec 22, 2008Founded Karyopharm Therapeutics Inc. is founded46

Filings

424 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 72 major events, 209 insider forms, 63 large holders, 1 private raises, 59 other. The latest 20:

  1. Oct 14, 20268-K EDGAR
  2. Oct 8, 2026SCHEDULE 13G/A EDGAR
  3. Oct 2, 20264 EDGAR
  4. Sep 25, 2026SCHEDULE 13G/A EDGAR
  5. Sep 25, 2026SCHEDULE 13G/A EDGAR
  6. Sep 18, 20268-K EDGAR
  7. Sep 11, 20268-K EDGAR
  8. Sep 4, 2026SCHEDULE 13G EDGAR
  9. Sep 2, 20264 EDGAR
  10. Aug 31, 20268-K EDGAR
  11. Aug 14, 2026SCHEDULE 13G/A EDGAR
  12. Aug 14, 2026SCHEDULE 13G/A EDGAR
  13. Aug 13, 202610-Q EDGAR
  14. Aug 13, 20268-K EDGAR
  15. Aug 12, 2026SCHEDULE 13G/A EDGAR
  16. Aug 11, 2026SCHEDULE 13G/A EDGAR
  17. Jul 31, 20268-K EDGAR
  18. Jul 30, 20264 EDGAR
  19. Jul 28, 2026SCHEDULE 13G EDGAR
  20. Jul 17, 20268-K EDGAR

The 424 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 63 such filings since October 2021, the latest 10:

  1. Oct 8, 2026SCHEDULE 13G/A
  2. Sep 25, 2026SCHEDULE 13G/A
  3. Sep 25, 2026SCHEDULE 13G/A
  4. Sep 4, 2026SCHEDULE 13G
  5. Aug 14, 2026SCHEDULE 13G/A
  6. Aug 14, 2026SCHEDULE 13G/A
  7. Aug 12, 2026SCHEDULE 13G/A
  8. Aug 11, 2026SCHEDULE 13G/A
  9. Jul 28, 2026SCHEDULE 13G
  10. Jun 5, 2026SCHEDULE 13G/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Dec 7, 2022Raised $165 million in a private offering of equity Form D: 33 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 96. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Ra Capital Management, L.P.1,917,354$18.7M0.2%No change
Adage Capital Partners Gp, L.l.c.1,521,322$14.9M0.0%−285,000
Acorn Capital Advisors, LLC1,518,113$14.8M4.0%+1,230,287
Goldman Sachs Group Inc1,424,658$13.9M0.0%+477,079
BlackRock, Inc.1,418,799$13.9M0.0%+1,173,900
Kalehua Capital Management LLC1,371,288$13.4M4.3%New
Vanguard Capital Management LLC958,979$9.4M0.0%+219,234
Catalio Capital Management, LP940,855$9.2M1.7%+43,146
Avidity Partners Management LP924,487$9.0M1.4%−2,995
Two Sigma Investments, LP695,264$6.8M0.0%+544,032
NEA Management Company, LLC576,780$5.6M0.4%New
Geode Capital Management, LLC531,231$5.2M0.0%+325,098
Ghisallo Capital Management LLC500,000$4.9M0.1%New
Soleus Capital Management, L.P.440,000$4.3M0.1%No change
UBS Group AG353,545$3.5M0.0%+159,528
State Street Corp325,991$3.2M0.0%+245,249
Affinity Asset Advisors, LLC312,500$3.1M0.2%−187,500
Brevan Howard Capital Management LP309,817$3.0M0.0%+97,450
Millennium Management LLC305,676$3.0M0.0%−114,895
Boxer Capital Management, LLC302,536$3.0M0.2%No change
Davidson Kempner Capital Management LP300,000$2.9M0.1%No change
Silverarc Capital Management, LLC297,460$2.9M0.3%New
Eversept Partners, LP276,174$2.7M0.1%No change
Jpmorgan Chase & Co207,609$2.1M0.0%+207,138
Morgan Stanley202,506$2.0M0.0%+183,936

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46